Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

VBI Vaccines Inc. (VBIV)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.0500+0.1400 (+7.33%)
At close: 04:00PM EST
2.0400 -0.01 (-0.49%)
After hours: 07:29PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.9100
Open1.9100
Bid2.0000 x 900
Ask2.0400 x 40700
Day's Range1.8700 - 2.0600
52 Week Range1.8600 - 4.8300
Volume2,578,200
Avg. Volume3,519,060
Market Cap527.475M
Beta (5Y Monthly)1.94
PE Ratio (TTM)N/A
EPS (TTM)-0.2640
Earnings DateFeb 28, 2022 - Mar 04, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.00
  • Business Wire

    VBI Vaccines Announces Dosing of First Patient in Second Phase 2 Study in Chronic Hepatitis B Patients as Part of Expansion of Clinical Collaboration With Brii Bio

    CAMBRIDGE, Mass., January 05, 2022--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that the first patient has been dosed in a second Phase 2a/2b clinical study evaluating VBI-2601 (BRII-179), an immunotherapeutic candidate targeting chronic hepatitis B virus (HBV). This newly announced Phase 2 study will assess VBI-2601 as an add-on therapy to the standard-of-care, nucleos(t)

  • TipRanks

    These 2 “Strong Buy” Penny Stocks Are Poised to Take Off, Says Raymond James

    Let’s talk about penny stocks. These are equities that trade for less than $5 per share, the very bottom of the price range. While they are priced that low for a reason – and the reasons may vary – low price in itself doesn’t mean that the stock’s fundamentals are sour. Smart investors can find some true bargains among the penny stocks, and set themselves up for outsized gains. The opportunity is linked to a simple question: Why is the company’s stock priced so low? If the answer is mainly benig

  • Business Wire

    VBI Vaccines Announces Filing of New Drug Submission for 3-Antigen Hepatitis B Vaccine to Health Canada

    CAMBRIDGE, Mass., December 09, 2021--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced the filing of a New Drug Submission (NDS) to Health Canada for the Company’s 3-antigen prophylactic hepatitis B vaccine candidate, seeking approval in Canada for the prevention of infection caused by all known subtypes of the hepatitis B virus in adults.

Advertisement
Advertisement